Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546

Related Posts

Tuberculosis treatment failure associated with evolution of antibiotic resilience

Click to expand

December 9, 2022

Qingyun Liu, Junhao Zhu , Charles L Dulberger , Sydney Stanley, Sean Wilson, Eun Seon Chung, Xin Wang, Peter Culviner, Yue J Liu, Nathan D Hicks, Gregory H Babunovic, Samantha R Giffen, Bree B Aldridge, Ethan C Garner, Eric J Rubin, Michael C Chao, Sarah M Fortune

Science. 2022 Dec 9;378(6624):1111-1118. doi: 10.1126/science.abq2787. Epub 2022 Dec 8.
PMID: 36480634 | DOI: 10.1126/science.abq2787


Introduction: The widespread use of antibiotics has placed bacterial pathogens under intense pressure to evolve new survival mechanisms. Genomic analysis of 51,229 Mycobacterium tuberculosis (Mtb)clinical isolates has identified an essential transcriptional regulator, Rv1830, herein called resR for resilience regulator, as a frequent target of positive (adaptive) selection. resR mutants do not show canonical drug resistance or drug tolerance but instead shorten the post-antibiotic effect, meaning that they enable Mtb to resume growth after drug exposure substantially faster than wild-type strains. We refer to this phenotype as antibiotic resilience. ResR acts in a regulatory cascade with other transcription factors controlling cell growth and division, which are also under positive selection in clinical isolates of Mtb. Mutations of these genes are associated with treatment failure and the acquisition of canonical drug resistance.

Source: https://pubmed.ncbi.nlm.nih.gov/36480634/